Form 4: Esperion Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 108 shares of common stock on July 17, 2024, to satisfy tax obligations related to vested restricted stock units.
Summary
- On July 17, 2024, Eric Warren, Chief Commercial Officer of Esperion Therapeutics, sold 108 shares of common stock.
- The shares were sold at a price of $2.587 per share.
- The transaction was executed to cover tax obligations arising from the vesting of restricted stock units.
- Following the transaction, Warren directly owns 165,478 shares of Esperion Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an executive's stock sale for tax purposes. It doesn't convey any particularly positive or negative sentiment regarding the company's prospects.
Industry Context
Executive stock sales are a common occurrence and are often related to personal financial planning or tax obligations. The sale itself is unlikely to have a significant impact on the company's overall performance or stock price.
Key Dates
| Date | Description |
|---|---|
| February 28, 2022 | Date of execution of the Limited Power of Attorney. |
| July 17, 2024 | Date of the stock sale transaction. |
| July 18, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.